6v4t: Difference between revisions

← Older edit

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-'''Unreleased structure'''
-The entry 6v4t is ON HOLD  until Paper Publication
+==MPER-TMD of HIV-1 Env bound with the entry inhibitor S2C3==
+<StructureSection load='6v4t' size='340' side='right'caption='[[6v4t]]' scene=''>
+== Structural highlights ==
+<table><tr><td colspan='2'>[[6v4t]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6V4T OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6V4T FirstGlance]. <br>
+</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=QOJ:4-[10-(9-azanyl-2,3-dihydro-1~{H}-cyclopenta[b]quinolin-4-yl)decyl]-2,3-dihydro-1~{H}-cyclopenta[b]quinolin-9-amine'>QOJ</scene></td></tr>
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6v4t FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6v4t OCA], [https://pdbe.org/6v4t PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6v4t RCSB], [https://www.ebi.ac.uk/pdbsum/6v4t PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6v4t ProSAT]</span></td></tr>
+</table>
+== Function ==
+[https://www.uniprot.org/uniprot/Q74849_9HIV1 Q74849_9HIV1]
+<div style="background-color:#fffaf0;">
+== Publication Abstract from PubMed ==
+Combination antiretroviral therapy has transformed HIV-1 infection, once a fatal illness, into a manageable chronic condition. Drug resistance, severe side effects and treatment noncompliance bring challenges to combination antiretroviral therapy implementation in clinical settings and indicate the need for additional molecular targets. Here, we have identified several small-molecule fusion inhibitors, guided by a neutralizing antibody, against an extensively studied vaccine target-the membrane proximal external region (MPER) of the HIV-1 envelope spike. These compounds specifically inhibit the HIV-1 envelope-mediated membrane fusion by blocking CD4-induced conformational changes. An NMR structure of one compound complexed with a trimeric MPER construct reveals that the compound partially inserts into a hydrophobic pocket formed exclusively by the MPER residues, thereby stabilizing its prefusion conformation. These results suggest that the MPER is a potential therapeutic target for developing fusion inhibitors and that strategies employing an antibody-guided search for novel therapeutics may be applied to other human diseases.
-Authors: Xiao, T., Frey, G., Fu, Q., Lavine, C.L., Scott, D.A., Seaman, M.S., Chou, J.J., Chen, B.
+HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes.,Xiao T, Frey G, Fu Q, Lavine CL, Scott DA, Seaman MS, Chou JJ, Chen B Nat Chem Biol. 2020 Mar 9. pii: 10.1038/s41589-020-0496-y. doi:, 10.1038/s41589-020-0496-y. PMID:32152540<ref>PMID:32152540</ref>
-Description: MPER-TMD of HIV-1 Env bound with the entry inhibitor S2C3
+From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-[[Category: Unreleased Structures]]
+</div>
-[[Category: Fu, Q]]
+<div class="pdbe-citations 6v4t" style="background-color:#fffaf0;"></div>
-[[Category: Xiao, T]]
+== References ==
-[[Category: Lavine, C.L]]
+<references/>
-[[Category: Chen, B]]
+__TOC__
-[[Category: Seaman, M.S]]
+</StructureSection>
-[[Category: Chou, J.J]]
+[[Category: Human immunodeficiency virus 1]]
-[[Category: Frey, G]]
+[[Category: Large Structures]]
-[[Category: Scott, D.A]]
+[[Category: Chen B]]
+[[Category: Chou JJ]]
+[[Category: Frey G]]
+[[Category: Fu Q]]
+[[Category: Lavine CL]]
+[[Category: Scott DA]]
+[[Category: Seaman MS]]
+[[Category: Xiao T]]